- Home
- FSBC vs ALLO Comparison
FSBC vs ALLO Comparison
Compare FSBC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | ALLO |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 707.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FSBC | ALLO |
|---|---|---|
| Price | $43.41 | $1.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $41.90 | $8.35 |
| AVG Volume (30 Days) | 85.8K | ★ 7.0M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | 28.32 | ★ 34.09 |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | $142,416.42 |
| P/E Ratio | $49.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.26 | $0.99 |
| 52 Week High | $43.50 | $4.46 |
Technical Indicators
Market Signals| Indicator | FSBC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 35.71 |
| Support Level | $39.93 | $1.56 |
| Resistance Level | N/A | $1.92 |
| Average True Range (ATR) | 1.01 | 0.13 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 96.17 | 12.28 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).